WHAT IS NEOADJUVANT CHEMOTHERAPY?
- Neoadjuvant kemoterapi, kas invaziv mesane kanserinde cerrahi öncesi mikroskobik hücreleri yok etmek ve sağkalımı artırmak amacıyla uygulanan standart bir tedavi yöntemidir.
- 2026 EAU kılavuzlarına göre, bu tedavi özellikle böbrek fonksiyonu uygun olan hastalarda cisplatin bazlı kombinasyonlar şeklinde uygulanmalıdır.
- Tedavi süreci, cerrahi başarıyı optimize etmek için multidisipliner bir yaklaşımla planlanmalı ve operasyon zamanlamasında gereksiz gecikmelerden kaçınılmalıdır.
İçerik yapay zeka ile optimize edilmiştir
Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer (MIBC)
Neoadjuvant chemotherapy is a systemic drug treatment administered before radical cystectomy in appropriately selected patients with Muscle-Invasive Bladder Cancer (MIBC). The primary goals of this approach are to eliminate microscopic cancer cells that may have spread beyond the bladder, reduce tumor burden, and improve surgical outcomes. According to the 2026 European Association of Urology (EAU) Guidelines, cisplatin-based neoadjuvant chemotherapy is the standard of care for eligible patients to increase long-term survival.
What is Neoadjuvant Chemotherapy?
Neoadjuvant chemotherapy is a specialized drug treatment administered specifically before bladder cancer surgery. Unlike local treatments that target only the bladder, chemotherapy circulates throughout the entire body via the bloodstream.
This systemic approach aims to destroy not only the visible bladder tumor but also microscopic cancer cells that cannot yet be detected by conventional imaging studies. By addressing these hidden cells early, the treatment provides a more comprehensive oncological defense.
Why is Chemotherapy Given Before Surgery?
The administration of chemotherapy prior to surgical intervention serves several critical clinical objectives. These goals are designed to optimize the patient's overall prognosis and surgical success:
- Eliminate microscopic metastatic disease that may exist outside the primary site.
- Reduce tumor burden, making the primary mass more manageable for removal.
- Improve the likelihood of complete surgical removal (negative margins).
- Increase long-term survival rates for MIBC patients.
- Improve overall oncological outcomes through a multi-staged approach.
Who is Eligible for This Treatment?
According to the 2026 EAU Guidelines, neoadjuvant chemotherapy is not suitable for every patient. It should be specifically considered for individuals who meet the following criteria:
| Criteria | Requirement |
|---|---|
| Diagnosis | Muscle-Invasive Bladder Cancer (MIBC) |
| Organ Function | Adequate kidney function to tolerate cisplatin |
| Health Status | Good overall performance status |
| Contraindications | No major medical barriers to systemic chemotherapy |
All treatment decisions should always be made within a multidisciplinary team to ensure patient safety and treatment efficacy.
Chemotherapy Regimens and Surgical Timing
The current standard treatment consists of cisplatin-based combination chemotherapy. The selection of the most appropriate regimen depends on the patient's kidney function, overall health, performance status, and other individual medical factors.
Following the completion of the chemotherapy cycles, patients undergo a repeat clinical evaluation. If the patient is deemed appropriate, radical cystectomy with pelvic lymph node dissection is performed without unnecessary delay to ensure the best curative results.
Potential Side Effects and Monitoring
As with all systemic treatments, neoadjuvant chemotherapy may cause certain side effects. Patients are closely monitored throughout the process, and supportive care is provided to minimize these effects:
- Nausea and vomiting
- Fatigue and general malaise
- Temporary reductions in blood cell counts
- Increased risk of infection
- Kidney function changes in selected patients
EAU 2026 Key Message for Patients
The 2026 European Association of Urology (EAU) Guidelines emphasize that cisplatin-based neoadjuvant chemotherapy should be offered to eligible patients with Muscle-Invasive Bladder Cancer. This recommendation is based on evidence showing significant improvements in long-term survival. It is vital that treatment is carefully coordinated to avoid any unnecessary delays in the transition to surgery.
Multidisciplinary Treatment Planning with Assoc. Prof. Dr. Serdar Yalçın
Assoc. Prof. Dr. Serdar Yalçın evaluates patients with Muscle-Invasive Bladder Cancer in Bodrum, Türkiye, utilizing a multidisciplinary collaboration. This team involves experts from medical oncology, radiology, pathology, and other relevant specialties to provide a holistic treatment plan.
Each patient's pathway—including neoadjuvant chemotherapy, robotic radical cystectomy, pelvic lymph node dissection, and urinary diversion—is individualized according to the latest EAU Guidelines. Patients from Bodrum, Muğla, and across Türkiye, as well as international patients, seek consultation for:
- Detailed and transparent communication.
- Evidence-based treatment recommendations.
- Multidisciplinary decision-making processes.
- Individualized care and continuous support at every stage.
Frequently Asked Questions (FAQ)
Will chemotherapy delay my surgery? No. The goal is to improve cancer outcomes before surgery while maintaining an appropriate and safe treatment timeline.
Can every patient receive neoadjuvant chemotherapy? No. Eligibility depends primarily on kidney function, overall health, and the specific ability to tolerate cisplatin-based treatments.
Will I still need surgery after chemotherapy? In most eligible patients, yes. Radical cystectomy remains a key component of the curative treatment plan for muscle-invasive bladder cancer.
Conclusion Neoadjuvant chemotherapy is an essential component of modern treatment for MIBC. Careful patient selection, timely administration, and definitive surgery according to current international guidelines significantly improve long-term oncological outcomes.
